Cancer Treatment Milestone at Scripps MD Anderson
SAN DIEGO (KUSI) – Scripps MD Anderson Cancer Center has reached a milestone with a new drug.
The center has become the first in the county to administer what’s being described as new targeted cancer therapy.
The drug is called Lutathera which uses radioactively charged proteins that attack and destroy neuroendocrine tumors of the digestive tract. According to doctors after being infused intravenously, the drug attaches to a receptor in the tumor cell like a magnet. Once inside the cells, it emits radiation, killing the cancer cells and shrinking the tumor.
Lutathera treatment is available to patients at the Scripps MD Anderson Cancer Center, where medical oncologists Dr. Darren Sigal and Dr. Marin Xavier serve as the therapy’s ordering physicians. It was approved by the U.S. Food and Drug Administration earlier this year.